(+/-)-1-hydroxy-N-(2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)-2-naphthamide | 1258936-28-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (+/-)-1-hydroxy-N-(2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)-2-naphthamide
• 英文别名: 1-hydroxy-N-(2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)naphthalene-2-carboxamide
• CAS: 1258936-28-5
• 化学式: C₁₇H₁₃NO₅
• 分子量: 311.294
• InChiKey: YFFGXPVGJCVLMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  99.2
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] OXABICYCLO [4.1.O]HEPT-B-EN-S-YLCARBAMOYL DERIVATIVES INHIBITING THE NUCLEAR FACTOR-KAPPA(B) - (NF-KB)<br/>[FR] DÉRIVÉS D'OXABICYCLO[4.1.0]HEPT-B-EN-S-YLCARBAMOYLE INHIBANT LE FACTEUR NUCLÉAIRE KAPPA(B)-(NF-?B)
  申请人：PROFECTUS BIOSCIENCES INC

  公开号：WO2010148042A1

  公开（公告）日：2010-12-23

  The invention relates to compounds of formula (I), formula (II), formula (III) and formula (IV),and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries.

  该发明涉及式(I)、式(II)、式(III)和式(IV)的化合物，以及这些化合物的药用盐，用于治疗癌症、炎症、自身免疫疾病、糖尿病和糖尿病并发症、感染、心血管疾病和缺血再灌注损伤。
• Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB)
  申请人：Zhang Jie

  公开号：US20120046357A1

  公开（公告）日：2012-02-23

  The invention relates to compounds of formula (1) and formula (2), and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries, wherein R 1 is defined herein.

  本发明涉及式（1）和式（2）的化合物，以及其药学上可接受的盐，用于治疗癌症、炎症、自身免疫疾病、糖尿病和糖尿病并发症、感染、心血管疾病和缺血再灌注损伤，其中R1在此定义。
• OXABICYCLO [4.1.O]HEPT-B-EN-S-YLCARBAMOYL DERIVATIVES INHIBITING THE NUCLEAR FACTOR-KAPPA(B) - (NF-KB)
  申请人：Profectus Biosciences, Inc.

  公开号：EP2443103A1

  公开（公告）日：2012-04-25
• Oxabicyclo[4.1.0]Hept-B-en-S-yl Carbamoyl Derivatives Inhibiting The Nuclear Factor-Kappa (B) - (NF-KB)
  申请人：Zhang Jie

  公开号：US20120088827A1

  公开（公告）日：2012-04-12

  The invention relates to compounds of formula (I), formula (II), formula (III) and formula (IV), and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries.